Currently the standard practice in tumor biomarker research still relies on invasive tumor biopsy from local sites followed by molecular testing or NGS assay. However, this only provides a very limited characterization of tumor composition. Recent studies in non-invasive biomarker research have demonstrated the potential advantages of using cell-free nucleic acids isolated from blood plasma to study genetic heterogeneity of tumor population and dissect the complex cancer clonal architecture. Overall, this study demonstrates that Oncomine™ Pan-Cancer Cell-Free Assay provides a unique and complete NGS solution for comprehensive genetic mutation assessment using in vitro and in vivo liquid biopsy models.
Please fill out the form below to download this poster.